Read the latest positive news, breakthroughs, and inspiring stories about multiple myeloma, curated daily by BrightWire.
A groundbreaking six-year study shows that 81% of newly diagnosed multiple myeloma patients treated with a Darzalex regimen have experienced no cancer progression. Many patients have even been able to stop treatment while remaining disease-free.
Bristol Myers Squibb reports encouraging results for a cutting-edge therapy helping multiple myeloma patients who've run out of options. The CAR T-cell treatment offers fresh hope for those battling this challenging blood cancer.
Multiple myeloma patients who've run out of options now have new hope with a groundbreaking pill that works differently than any drug before it. The FDA just approved iberdomide, a molecular glue that helps the body destroy cancer cells more effectively.
Adults battling multiple myeloma just gained a powerful new weapon in their fight. The FDA has approved Zenbexus, the first drug in an entirely new class of treatments for this incurable blood cancer.
A groundbreaking new cancer treatment just became available for multiple myeloma patients facing their first relapse, doubling the chances of achieving the deepest level of cancer response. The FDA approved ZENBEXUS, the first drug in an entirely new treatment class that could transform how doctors fight this blood cancer.
An investigational therapy for multiple myeloma shrank tumors in over 40% of heavily pre-treated patients, offering hope through a completely new treatment pathway. Even better, patients get a break after one year instead of lifelong infusions.
A major clinical trial shows multiple myeloma patients can safely stop maintenance therapy after two years instead of continuing indefinitely. The discovery could reduce treatment burden and costs while maintaining the same survival rates.
A groundbreaking immunotherapy combination helped 8 in 10 multiple myeloma patients live two years without their cancer getting worse, compared to just 5 in 10 with standard treatment. The global trial involving over 860 patients offers renewed hope for those facing this difficult blood cancer.
A new immunotherapy combination is helping eight out of ten multiple myeloma patients live two years without their cancer getting worse, doubling the success rate of standard treatment. The international trial involving over 860 patients offers fresh hope for people fighting this challenging blood cancer.
A breakthrough immunotherapy combination helped eight in 10 multiple myeloma patients live two years without their cancer worsening, nearly doubling the success rate of standard treatment. The results from a global trial of over 860 patients offer renewed hope for families facing this difficult blood cancer.
After nearly 12 years of chemotherapy for multiple myeloma, personal trainer Tony Newberne is cancer-free thanks to groundbreaking CAR-T therapy. Now he's urging others to advocate for their own health and explore all treatment options.
When Black and white multiple myeloma patients receive the same modern treatments, they survive at equal rates. A Cleveland Clinic study proves access to care, not biology, drives health disparities.